 |
MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a collaboration with UniQuest Pty Ltd (UniQuest), the commercialisation company of The University of Queensland (UQ), to develop a radiolabelled molecule targeting an immune checkpoint protein. The announcement was made at the AusBiotech 2022 national conference, currently being held in Perth, Western Australia.
Under the agreement, Telix and UniQuest will work together to adapt and refine an undisclosed targeting peptide – developed in the laboratory of Professor David Craik in the Institute for Molecular Bioscience. The goal is that an immune targeting peptide would be used as an imaging agent to determine the presence of certain immune checkpoint proteins in metastatic tumours, in order to guide patient selection for immunotherapy.
Immune checkpoints are a normal part of the immune system, which modulate the body's defensive responses to protect normal healthy cells from being destroyed when the immune system is activated.
They do this by engaging with partner molecules on the surface of immune cells – known as immune checkpoint proteins – signaling to leave healthy cells alone. Some tumours have co-opted this mechanism, which can help cancer to hide from an immune attack. Drugs called immune checkpoint inhibitors disrupt this suppression of the immune system by blocking immune checkpoints from binding with their partner molecules. However, responses are highly variable.
Dr. Michael Wheatcroft, Chief Scientist at Telix Pharmaceuticals said, "Immune checkpoint inhibitors have demonstrated the power of immunotherapy, however in most cases it is still a minority of treated patients that respond. There is an urgent need for tools that can predict when a patient is likely to respond to this treatment. Currently, this is done by an invasive biopsy, with results that can be misleading since checkpoint protein expression can be extremely heterogenous both within a single tumour and between metastatic tumours.
"We are pleased to be working with Professor Craik and his lab, and to apply our expertise in radiopharmaceuticals to further advance this exciting new technology first developed at UQ. By using targeted radiation to assess the status and presence of this checkpoint protein throughout the body, we can potentially find a non-invasive method to paint a more useful picture of this immunotherapy target, and better select patients suitable for treatment."
UniQuest CEO Dr Dean Moss added, "I am pleased to see this UQ innovation advance through a collaboration with an Australian-headquartered global biotech, with deep expertise in biologics as radiopharmaceuticals. UniQuest has a strong track record of commercialisation and we look forward to working with Telix to continue the development of this peptide, with the aim to support clinical translation in a field of high scientific interest and relevance to patients."
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix's lead product, Illuccix (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11 injection, has been approved by the Australian Therapeutic Goods Administration (TGA),[1] and by the U.S. Food and Drug Administration (FDA),[2] and by Health Canada.[3]
This announcement has been authorised for release by Dr. Christian Behrenbruch, Managing Director and Group Chief Executive Officer.
Legal Notices
This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.
To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.
The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
[1] ASX disclosure 2 November 2021.
[2] ASX disclosure 20 December 2021.
[3] ASX disclosure 14 October 2022.
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com